DE122005000041I2 - Nukleotidanaloga. - Google Patents

Nukleotidanaloga.

Info

Publication number
DE122005000041I2
DE122005000041I2 DE200512000041 DE122005000041C DE122005000041I2 DE 122005000041 I2 DE122005000041 I2 DE 122005000041I2 DE 200512000041 DE200512000041 DE 200512000041 DE 122005000041 C DE122005000041 C DE 122005000041C DE 122005000041 I2 DE122005000041 I2 DE 122005000041I2
Authority
DE
Germany
Prior art keywords
nucleotide analogs
compounds
relates
tautomers
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE200512000041
Other languages
English (en)
Other versions
DE122005000041I1 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24757965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122005000041(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority claimed from PCT/US1997/013244 external-priority patent/WO1998004569A1/en
Publication of DE122005000041I1 publication Critical patent/DE122005000041I1/de
Publication of DE122005000041I2 publication Critical patent/DE122005000041I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
DE200512000041 1996-07-26 1997-07-25 Nukleotidanaloga. Active DE122005000041I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68683896A 1996-07-26 1996-07-26
PCT/US1997/013244 WO1998004569A1 (en) 1996-07-26 1997-07-25 Nucleotide analogs

Publications (2)

Publication Number Publication Date
DE122005000041I1 DE122005000041I1 (de) 2005-10-20
DE122005000041I2 true DE122005000041I2 (de) 2012-05-24

Family

ID=24757965

Family Applications (3)

Application Number Title Priority Date Filing Date
DE200512000041 Active DE122005000041I2 (de) 1996-07-26 1997-07-25 Nukleotidanaloga.
DE69722004T Expired - Lifetime DE69722004T2 (de) 1996-07-26 1997-07-25 Nukleotidanaloga
DE122008000033C Pending DE122008000033I1 (de) 1996-07-26 1997-07-25 Nukleotidanaloga

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69722004T Expired - Lifetime DE69722004T2 (de) 1996-07-26 1997-07-25 Nukleotidanaloga
DE122008000033C Pending DE122008000033I1 (de) 1996-07-26 1997-07-25 Nukleotidanaloga

Country Status (14)

Country Link
EP (1) EP0915894B1 (de)
KR (1) KR100619298B1 (de)
CN (2) CN100384859C (de)
AT (1) ATE240339T1 (de)
AU (1) AU713374B2 (de)
DE (3) DE122005000041I2 (de)
DK (1) DK0915894T3 (de)
ES (1) ES2198003T3 (de)
FR (1) FR05C0032I2 (de)
HK (1) HK1020964A1 (de)
LU (2) LU91178I2 (de)
NL (2) NL300202I1 (de)
NZ (1) NZ333687A (de)
PT (1) PT915894E (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100396689C (zh) * 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物
CN102453055B (zh) * 2010-10-29 2015-04-01 上海迪赛诺医药发展有限公司 制备(r)-9-(2-膦酰甲氧基丙基)腺嘌呤双(异丙氧羰基氧甲基)酯的方法
CN102887901B (zh) * 2011-07-01 2015-01-07 四川好医生攀西药业有限责任公司 无环核苷酸类似物及其制备方法和应用
UA115311C2 (uk) 2011-08-16 2017-10-25 Гіліад Сайєнсіз, Інк. Геміфумарат тенофовіру алафенаміду
CN103232490B (zh) * 2013-01-31 2015-06-10 洛阳聚慧投资股份有限公司 具有抑制hiv-1/hbv病毒复制活性的核苷类化合物、制备方法及抗病毒方面的应用
CN103242366B (zh) * 2012-08-13 2014-08-20 洛阳聚慧投资股份有限公司 一组替诺福韦酯化合物、制备方法及其在抗病毒方面的应用
CN104230934B (zh) * 2013-06-08 2016-12-28 上海医药工业研究院 一种化合物及其制备方法和用途
EP2860184B1 (de) 2013-10-09 2018-08-29 Zentiva, k.s. Dihydrogenphosphatsalz von Tenofovirdisoproxil
CN104844459B (zh) * 2014-02-18 2016-08-24 扬州三友合成化工有限公司 一种氯甲基异丙基碳酸酯的制备方法
CN103880884A (zh) * 2014-03-21 2014-06-25 浙江苏泊尔制药有限公司 一种高纯度富马酸泰诺福韦酯的制备方法
CN104098605B (zh) * 2014-07-30 2015-09-30 福建广生堂药业股份有限公司 一种适合于工业化生产的替诺福韦制备方法
KR101703257B1 (ko) 2014-09-30 2017-02-06 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
KR101703258B1 (ko) 2014-12-30 2017-02-06 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
CN105985381B (zh) * 2014-12-30 2018-10-30 安徽贝克联合制药有限公司 一种替诺福韦的制备方法
KR101761466B1 (ko) * 2015-01-20 2017-07-26 씨제이헬스케어 주식회사 신규한 테노포비어 디소프록실 캠실레이트, 이의 결정형 및 이의 제조방법
CN106349289A (zh) * 2016-08-03 2017-01-25 上海延安药业有限公司 替诺福韦酯原料药及片剂
KR101909570B1 (ko) * 2016-12-05 2018-10-19 (주) 성운파마코피아 고순도 테노포비어 디소프록실 제조방법
CN108358968B (zh) * 2018-04-03 2020-09-15 科兴生物制药股份有限公司 一种替诺福韦的制备方法
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2111043B (en) * 1980-12-12 1985-02-06 Ciba Geigy Ag Novel cephalosporin esters
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
ATE167679T1 (de) * 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
CA2054126A1 (en) * 1990-10-26 1992-04-27 Michiyuki Sendai Cephem compounds, their production and use
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
WO1995032957A1 (en) * 1994-05-27 1995-12-07 Astra Aktiebolag Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles

Also Published As

Publication number Publication date
ES2198003T3 (es) 2004-01-16
LU91178I9 (de) 2018-12-28
NL300202I1 (nl) 2005-09-01
DE69722004D1 (de) 2003-06-18
KR100619298B1 (ko) 2006-09-08
CN100384859C (zh) 2008-04-30
KR20000029705A (ko) 2000-05-25
CN101239989A (zh) 2008-08-13
AU3897097A (en) 1998-02-20
LU91433I2 (fr) 2008-06-30
NL300344I1 (nl) 2008-07-01
DE122008000033I1 (de) 2008-10-02
DE122005000041I1 (de) 2005-10-20
PT915894E (pt) 2003-10-31
ATE240339T1 (de) 2003-05-15
FR05C0032I2 (fr) 2006-12-29
HK1020964A1 (en) 2000-05-26
CN101239989B (zh) 2012-12-12
DE69722004T2 (de) 2004-04-01
NZ333687A (en) 2000-08-25
LU91178I2 (fr) 2005-08-22
EP0915894A1 (de) 1999-05-19
DK0915894T3 (da) 2003-09-15
EP0915894B1 (de) 2003-05-14
CN1244200A (zh) 2000-02-09
FR05C0032I1 (de) 2005-08-26
AU713374B2 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
NL300202I1 (nl) Nucleotide-analogen.
BR9815166A (pt) "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral"
FI921030A (fi) Cykliska ureaderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DE69705829T2 (de) Meta-substituierte phenylsulphonamidderivate
AUPR213700A0 (en) Antiviral agents
DK0923554T3 (da) N-Benzylpiperidin- og tetrahydropyridinderivater
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
NO954072D0 (no) Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler
NO20001514L (no) Vitronectin-reseptor-antagonist
YU30603A (sh) Derivati premošćenog piperazina
CA2168937A1 (en) Anti-neurodegeneratively active 10-aminoaliphatyl-dibenz[b,f]oxepines
AP9801377A0 (en) Tricyclic erythromycin derivatives.
EP1019047A4 (de) Antithrombotische mittel
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
DE69828390D1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
AP9801235A0 (en) Erythromycin derivatives.
EA200000261A3 (ru) Новые замещенные димерные соединения, способ их получения и содержащияся их фармацевтическая композиция
DK0796256T3 (da) Fremgangsmåde til fremstilling af ranitidin
ATE301997T1 (de) Antivirale therapie
FR2598914B1 (fr) Composition prophylactique et curative pour l'arteriosclerose
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
EP0218195A3 (de) Bis-(Dibenzo[b,d]pyranyloxy)-propane